Tenax Therapeutics Insider Adds 80K Stock Options in July 2025
Rhea-AI Filing Summary
Tenax Therapeutics (TENX) filed a Form 4 disclosing insider activity by director Michael H. Davidson on 1 July 2025.
- Equity grant: Davidson acquired 80,000 stock options with an exercise price of $5.75. The options become exercisable on 01-Jul-2026 and expire on 01-Jul-2035. No cash was paid at grant (price $0.00).
- Existing derivative holdings: The filing shows additional option positions of 100,000 options at $5.94, two small option lots (4 each) at $3,200 and $992, a 47,500 pre-funded warrant (strike $0.01, no expiration) and a 25,000 warrant (strike $4.50) that will lapse upon the earlier of several milestone events or 08-Aug-2029.
- Common shares: Davidson owns 2,881 shares directly after the reported transaction.
- Total derivative exposure: The table indicates 252,508 derivative securities (options + warrants) now beneficially owned.
No sales or dispositions of Tenax common stock were reported. The transactions appear to be part of routine director compensation and warrant structures related to prior financing rounds.
Positive
- None.
Negative
- None.
Insights
TL;DR Neutral filing; director received 80k options, no open-market buying or selling.
The Form 4 shows a standard compensation grant—80,000 options at $5.75 with a 1-year vest and 10-year term—plus previously disclosed warrants. Because the grant carries no immediate cash cost and does not alter Tenax’s share count today, the market impact is limited. Investors may note continued insider alignment through sizeable option exposure (≈252k shares), but the absence of direct share purchases tempers any bullish signal. Overall, this is a routine governance disclosure rather than a catalyst.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 80,000 | $0.00 | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Pre-Funded Warrant | -- | -- | -- |
| holding | Warrant | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The pre-funded warrant has no expiration date. The warrant will expire on the earlier of (i) thirty (30) trading days following the date of the Issuer's initial public announcement of topline data from its Phase 3 LEVEL Study (LEVosimendan to Improve Exercise Limitation in PH-HFpEF Patients) ( NCT05983250 ) (the "Topline Data Announcement"); (ii) proportionally upon the exercise of the Reporting Person's pre-funded warrant issued on August 8, 2024, if such exercise is prior to the Topline Data Announcement; and (iii) August 8, 2029.
